معرفی
Min Chen, Ph.D. is an Assistant Professor in the Department of Toxicology and Cancer Biology at the University of Kentucky College of Medicine. Dr. Chen is also a member of the Markey Cancer Center/Cancer Research Priority Initiative and the Molecular and Cellular Oncology Research Program.
Dr. Chen's educational background includes a Doctor of Philosophy from the University of Texas Medical (2011), a Master of Science from the Chinese Academy of Sciences (1997), and a Doctor of Medicine from Anhui Medical University (1992).
Dr. Chen's research focuses on lung cancer invasion, metastasis and therapeutic resistance. Their work primarily investigates the role of integrin signaling pathways in cancer progression, with particular emphasis on Integrin α6β4 in breast and lung cancer models. Research areas include cancer cell invasion mechanisms, metastasis, therapeutic resistance, cancer epigenetics, and tryptophan metabolism in triple-negative breast cancer. The research demonstrates significant expertise in integrin biology (100%), cancer cell biology (94%), S100A4 (67%), metastatic carcinoma (45%), lung cancer (44%), tumor invasion (40%), breast cancer (40%), and lysophosphatidic acid signaling (29%).
Dr. Chen's publication record demonstrates consistent contributions to cancer research, with recent articles focusing on integrin signaling pathways and their role in cancer metastasis. The research shows a strong trend toward understanding molecular mechanisms of cancer cell invasion and identifying potential therapeutic targets, particularly through the investigation of integrin α6β4 signaling in various cancer models.
- National Institute of General Medical Sciences: Pilot: Integrin a6ß4 Regulation of Tryptophan Metabolism in TNBC (2017-2026)
- National Cancer Institute: Integrin alpha6beta4 Regulation of Cancer Epigenetics (2019-2024)
- Army Medical Research and Materiel Command: A Novel Peptide Suppresses Invasion and Metastasis in Rictor-amplified Lung Cancer (2021-2023)
- KY Lung Cancer Research Fund: A Novel Peptide to Inhibit Rictor-amplified Lung Tumorigenesis (2018-2021)
- METAvivor Research and Support Incorporated: Characterizing Metastatic Breast Cancer Heterogeneity Through Post-Mortem Tissue Collection (2019-2020)
Dr. Chen collaborates extensively with researchers across multiple institutions, particularly with Dr. Kathleen O'Connor (listed as PI on several projects where Dr. Chen is CoI), as well as Dr. Jing Liu, Dr. Chi Wang, and other members of the Markey Cancer Center. Their work contributes to UN Sustainable Development Goals related to good health and well-being through cancer research aimed at improving understanding and treatment of cancer.
